FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

  • biotechnology industry,biotech company,clinical trials,Neos Therapeutics,Regulatory

Neos Therapeutics ($NEOS) got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

The drug, Cotempla XR-ODT, is an extended-release formulation of the active ingredient in Ritalin and other ADHD treatments, and it's slated for a final FDA decision by Nov. 9.

On Friday, Neos got word from regulators that, while reviewing Cotempla, the FDA "identified deficiencies that preclude discussion" of the drug's future label, the company said. The agency said the problem does not reflect its final opinion on Cotempla, according to Neos, but that's all the company knows about the issue, management said.

"Although the FDA has not provided us with any information regarding the nature of the deficiencies, we intend to work closely with the FDA to understand the nature of any such deficiencies once identified to us and resolve them as quickly as possible," Neos CEO Vipin Garg said in a statement.

Investors read the note as an troubling sign for Neos and its most-advanced drug, sending the company's shares down as much as 25% after hours on Tuesday.

Neos executed a $72 million IPO over the summer based in part on the potential of Cotempla, a formulation of methylphenidate designed to last for 12 hours. In filings with the SEC, Neos disclosed that the FDA inspected its production facility in May and cited it for a single instance of inadequate controls related to its computer systems. Neos said it responded to the agency in June and has corrected its system "to assure that changes in records are instituted only by authorized personnel."

Behind Cotempla, Neos' pipeline includes an extended-release formation of amphetamine, which is up for a final FDA decision in January.


This link:http://www.chemcd.com/news/19373.html

The ChemCD compiler finishing, shall not be reproduced without permission, for reprint please indicate the source。

comments powered by Disqus

Categories

Related News

Merck Announces FDA Acceptance of Biologics License Application for Bezlotoxumab, an Investigational Antitoxin for Prevention of Clostridium Difficile Infection Recurrence

Merck announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for bezlotoxumab, an investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence.

Sanofi and Regeneron Announce Sarilumab Biologics License Application Accepted for Review by US FDA

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for sarilumab.

First data backs efficacy of BMS' novel HIV drug

A Bristol-Myers Squibb (BMS) drug that causes immature HIV particles to be released from cells early, interrupting their lifecycle, has cleared a proof-of-concept study.

EU Rules Could Restrict Genetic Testing

Genetic testing describes the application of laboratory methods to look at a person’s genes (the inherited DNA instructions). Genetic tests can be used to diagnose a genetic condition; screen for a risk of developing a particular health problems; for the selection of treatments; or to assess responses to treatments.

CHMP adopts positive opinion of Edurant in adolescents with HIV-1

The CHMP has adopted a positive opinion recommending a change to the terms of the marketing authorisation for Janssen’s Edurant (rilpivirine) in the EU to extend the indication to adolescent patients aged 12 to <18 years with human immunodeficiency virus-1 (HIV-1) infection

FDA finds mystery 'deficiencies' with Neos' long-acting Ritalin on the eve of approval

Neos Therapeutics got an ominous note from the FDA just weeks ahead of the expected approval date for its long-acting ADHD treatment, clouding the future of the company's lead asset.

Pfizer's once-failed cancer drug wins the FDA's 'breakthrough' tag

Pfizer has found new hope for a former pipeline standout, picking up the FDA's coveted breakthrough therapy designation for a Phase III reclamation project in oncology.